

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

UNITED STATES OF AMERICA	:	
	:	
	:	
v.	:	
	:	CRIMINAL NO. 2:20-CR-00200-RBS
TEVA PHARMACEUTICALS	:	
USA, INC., AND	:	
GLENMARK PHARMACEUTICALS	:	
INC., USA	:	
	:	

AMENDED STIPULATED SCHEDULING ORDER

WHEREAS, on May 1, 2023, the Parties respectfully requested that the Court change the substantive motion deadline in this case to match the updated deadline for filing substantive motions in *United States v. Aprahamian*, 2:20-cr-00064-RBS, of September 18, 2023;

WHEREAS, on May 2, 2023, the Court requested the Parties submit to the Court an Amended Stipulated Scheduling Order for the Court's review;

WHEREAS, the Parties stipulate to and request that the Court enter the following Stipulated Scheduling Order:

Event	Category	Deadline
General Motions		
	Responses	Two weeks after motion
	Replies	One week after response
Substantive Motions	Opening Motions	September 18, 2023
	Responses	October 16, 2023
	Replies	October 30, 2023
Expert Disclosures	Government's Disclosures	December 18, 2023
	Defendants' Disclosures	February 26, 2024
404(b) Notice and <i>Brady/Giglio</i>		February 12, 2024
Pretrial Motions and Trial Memoranda	Pretrial Motions and Trial Memoranda	March 11, 2024
	Responses	March 25, 2024
	Replies	April 1, 2024
Hearing on Pretrial Motions		On request
Government Exhibit Lists and Witness Lists; Jencks Disclosures		April 8, 2024
Defense Exhibit Lists and Witness Lists*		April 22, 2024
Voir Dire Questions, Jury Instructions, Witness Lists, and Proposed Verdict Forms		April 22, 2024
Trial		May 6, 2024

*Defendants will disclose witnesses they will call and exhibits they intend to use in their cases-in-chief.

[signatures on the following pages]

Accordingly, it is **ORDERED** that the Stipulated Scheduling Order shall govern the proceedings in this case.

IT IS SO ORDERED.

SIGNED on this 5th day of May, 2023

BY THE COURT:

s/ R. Barclay Surrick

R. BARCLAY SURRICK, DISTRICT JUDGE

[attorney signatures on the following page]

/s/ Matthew W. Lunder

Matthew W. Lunder

Julia M. Maloney

James A. Ryan

Michael M. Sawers

U.S. Department of Justice
Antitrust Division
450 Fifth St. NW, Suite 11300
Washington, DC 20530
Telephone: (202) 305-1878

Attorneys for the United States of America

/s/ Stephen Stigall

R. Stephen Stigall (PA ID 78748)
David. L. Axelrod (PA ID 323792)
James A. Mitchell

BALLARD SPAHR LLP
1735 Market Street, 51st Floor
Philadelphia, PA 19103
Telephone: 215-665-8500
stigalls@ballardspahr.com
axelrodd@ballardspahr.com

Mark P. Ressler
KASOWITZ BENSON TORRES
LLP
1633 Broadway
New York, NY 10019
Telephone: 212-506-1700
mressler@kasowitz.com

*Attorneys for Defendant Teva
Pharmaceuticals USA, Inc.*

/s/ Beth A. Wilkinson

Beth A. Wilkinson (*pro hac vice*)
Brian L. Stekloff (*pro hac vice*)
Kosta S. Stojilkovic (*pro hac vice*)

WILKINSON STEKLOFF LLP 2001 M
Street NW, 10th Floor Washington, DC
20036 Telephone: (202) 847-4000
bwilkinson@wilkinsonwalsh.com
bstekloff@wilkinsonwalsh.com
kstojilkovic@wilkinsonwalsh.com

*Attorneys for Defendant Glenmark
Pharmaceuticals Inc., USA*